Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system diseases, using genomic data and biomarkers to support a precision-medicine approach. Its pipeline includes ANAVEX®2-73 (blarcamesine), in clinical development for Alzheimer’s… From the company’s description.
In fiscal 2025, Anavex Life Sciences Corp. reported a net loss of $46.38M. Operations used $39.04M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Anavex Life Sciences Corp. does
In the company’s own words
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system diseases, using genomic data and biomarkers to support a precision-medicine approach. Its pipeline includes ANAVEX®2-73 (blarcamesine), in clinical development for Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome, and ANAVEX®3-71, being studied for schizophrenia and under development for other cognitive disorders. Additional compounds are in clinical or preclinical development for indications including neurodevelopmental and neurodegenerative diseases, pain and cancer. The company’s programs are organized around individual drug candidates rather than reportable business segments. Its main clinical focus is on disorders including Alzheimer’s, Parkinson’s, Rett syndrome and schizophrenia, while its portfolio also includes preclinical research in areas such as Fragile X syndrome, epilepsy and frontotemporal dementia. Anavex reports no commercial product business in the provided description; its activities center on research and development and clinical testing. Its website is www.anavex.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEW YORK, NY
- Fiscal year end
- September
- CIK
- 1314052
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Anavex Life Sciences Corp. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Anavex Life Sciences Corp.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Anavex Life Sciences Corp. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Anavex Life Sciences Corp.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Anavex Life Sciences Corp.'s last four quarterly filings that the numbers alone won't show?”